EP2991480A1 - Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells - Google Patents

Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells

Info

Publication number
EP2991480A1
EP2991480A1 EP14718919.5A EP14718919A EP2991480A1 EP 2991480 A1 EP2991480 A1 EP 2991480A1 EP 14718919 A EP14718919 A EP 14718919A EP 2991480 A1 EP2991480 A1 EP 2991480A1
Authority
EP
European Patent Office
Prior art keywords
cells
peptide
signal
effector protein
affect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14718919.5A
Other languages
German (de)
French (fr)
Inventor
Frank Wehner
Philippe I. H. BASTIAENS
Lale Azer
Jens Christmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to EP14718919.5A priority Critical patent/EP2991480A1/en
Publication of EP2991480A1 publication Critical patent/EP2991480A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients

Definitions

  • the present invention relates to the use of a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of cells for cryo- conservation and to a method for cryopreservation of cells using such a signal or effector protein/peptide.
  • cryopreservation of cells A number of methods for cryopreservation of cells are known in the art and used routinely. Typically, these methods involve a slow cooling process, e.g. with cooling rate of about -l°C/min, to a temperatur well below the freezing point, e.g. around -50°C or even lower, and a relatively fast thawing process (such as 60°C/min).
  • a slow cooling process e.g. with cooling rate of about -l°C/min
  • a relatively fast thawing process such as 60°C/min.
  • cryoyprotectants may act via different mechanisms.
  • one class of cryoprotectants such as DMSO or glycerol, reduce the formation of ice crystals in the intracellular and/or extracellular space of the cells.
  • the freezing or thawing protocol is interrupted at about +5°C in order to add or safely remove the respective cryoprotectant.
  • the survival rates may vary over a wide range. Whereas most cell types have survial rates in the range from about 70-95%, for some cells, e.g. stem cells, the yield may be much lower, such as 1 % or even less.
  • cryoprotectants such as trehalose and other sugars or various long-chained polymers
  • trehalose and other sugars or various long-chained polymers are known to "stabilize" the cells and the addition of viscosity- increasing agents, such as gels, has also been reported to slightly improve the survival rates.
  • viscosity- increasing agents such as gels
  • cryoprotectants which are less toxic than the aditives commonly used (in particular DMSO and similar compounds) and which also result in a significant increase of the survival rates and vitality of the cells.
  • aditives commonly used in particular DMSO and similar compounds
  • no substances with really improved performance have been added to the list of established cryoprotectants .
  • WO 2005/094806 Al discloses the use of quaternary ammonium compounds which block transport through aquaporines i.a. for use as cryoprotectants.
  • US 5,919,614 Al describes a method for prolonging the preservation of human blod platelets (which are not
  • the main object of the present invention was to provide novel and improved means for the protection of cells during cryopreservation which do not involve the use of toxic compounds, can be readily implemented in established cryopreservation
  • the present invention provides the use of a signal or effector protein/peptide having at least one of the
  • - capable to affect the osmoregulation of cells - capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells,
  • the present invention provides a method for cryopreservation of cells, which method comprises at least the following steps:
  • cryoprotective effect means any effect which, after cryopreservation of target cells, results in an increase of the survival rates and/or
  • cryoprotectant is any agent which causes such an effect. If cells are subjected to a hypertonic stress, e.g. induced by increasing the external osmolarity, at physiological temperatures, i.e. about +35°C, the cells initially react like a osmometer by reducing their volume. This is due to the high water permeability of the plasma membrane caused on the molecular level by the presence of nearly ubiquitary expressed passive water channels, so-called aquaporins .
  • RVI regulatory volume increase
  • the freezing process during cryopreservation is also known to be accompanied by a dehydration of the cells.
  • a dehydration of the cells For example, at temperatures below -10 °C the formation of extracellular ice crystals results in a thermodynamically driven loss of water through the plasma membrane (Spindler et al. (2012), Cryobiology 64, 250-260).
  • Fig. 1 shows that the portion of the aqueous phase decreases from about 69% of the total cell volume at 35°C to about 17% of the total cell volume at 10°C (as indicated by the point of intersection of the regression line with the axis of the cell volume) and which is 25% of the control value at 35°C.
  • the implications associated with the osmoregulation of cells during cryopreservation have been largely disregarded in the past. It is only known to add osmolytes to an external cryomedium in order to assist the dehydration of the cells.
  • a considerable dehydration and concomitant shrinking of the cells is considered to be desirable or even required in order to prevent destruction of the membranes of the cells by the extending ice crystals, to cause the crystallization of less water in the cytoplasm, and to ensure that folded membrane material is available for closing cracks and cryo-defects when the fluidity of the membrane lipids is restored after thawing.
  • vasopressin in the Examples below, it is demonstrated that the addition of vasopressin to target cells to be cryopreserved actually improved the survival rate and viability of such cryo- preserved cells considerably.
  • the signal or effector protein/peptide used in the present invention is not especially limited and may be any protein or peptide or compound having at least one of the properties recited in claim 1.
  • a protein as defined herein comprises a sequence of at least 20 amino acids, such as 20 - 100 amino acids or more, whereas a peptide as defined herein comprises a sequence of about 2 - 19 amino acids, in particular 2 - 10 amino acids.
  • the amino acids may be naturally occurring amino acids or chemically modified derivatives thereof.
  • the signal or effector protein/peptide is selected from the group comprising proteins/peptides which effect the activity of aquaporins, ion, protein or sugar transporting systems.
  • proteins/peptides which effect the activity of aquaporins, ion, protein or sugar transporting systems.
  • a large number of such ion, protein or sugar transporting systems are well-known in the art and some non-limiting specific examples are NHEl, NKCC1 and SGLT1.
  • HICCs hypertonicity-induced cation channels
  • the signal or effector protein/peptide acts by activating said transporting systems, in particular ion channels as mentioned above, thus, the effector protein/- peptide may be more specifically denoted as an activator protein/peptide .
  • the signal or effector protein/peptide is selected from the group comprising antidiuretic hormones, such as the peptide hormone vasopressin and its derivatives, in particular derivatives wherein one or more amino acid substitutions have been effected without essentially diminishing its effector activity (e.g. the amino acid at position 8 may be arginine, lysine or another amino acid) , aldosteron and its derivatives, cytokines, in particular TNF-a, and other proteins/peptides that may affect HICCs.
  • antidiuretic hormones such as the peptide hormone vasopressin and its derivatives, in particular derivatives wherein one or more amino acid substitutions have been effected without essentially diminishing its effector activity (e.g. the amino acid at position
  • a hypertonicity-induced cation channel is the epithelial Na + channel ENaC and particularly its a subunit ENaC is regulated by vasopressin.
  • aENaC is expressed in a multitude of different cells (including non-epithelial cells as well) .
  • atlas EMBL-EB1 dated 23.4. 2013
  • 106 cell types and 389 cell lines expressing the same are known so far.
  • the osmoregulation and other transporting processes mediated by this ion channel of a large number of different cell types can be affected via vasopressin.
  • the signal or effector protein/peptide is present in the medium containing the cells in a
  • the medium may be any suitable medium known in the art, in particular any medium suitable for cultivation and maintainance of the respective cells.
  • the medium may be, e.g. DMEM or MEM.
  • the contacting step is conducted before cooling the cells to a temperature below 0°C.
  • the cells are incubated with the signal or effector
  • protein/peptide for a period in the range from 2 min to 48 hrs, preferably in the range from 1 h to 4 hrs, at a temperature in the range from 40°C to 0°C, preferably from 37°C to 0°C or 37°C to 4°C, more preferred about 37°C to 20°C, before cooling the cells to a temperature below 0°C.
  • the cells are preferably essentially separated from the signal or effector protein/peptide, e.g. by means of a medium exchange or dialysis, before cooling the cells to a temperature below 0°C.
  • the contacting step is conducted after cooling the cells to a temperature below 0°C and thawing the cells to a temperature above 0°C.
  • a first contacting step is conducted before cooling the cells to a temperature below 0°C and a second contacting step is conducted after cooling the cells to a temperature below 0°C and thawing the cells to a
  • the cells are cooled below 0°C with a cooling rate in the range from -5°C/min to -0.1 °C/min, preferably about -l°C/min, to a temperature in the range from -40°C to -196°C, preferably in the range from -50°C or -80°C to -196°C.
  • the cryomedium may be any suitable medium known in the art for cryopreservation . More specifically, the cryomedium may be selected from the group comprising a conventional cell culture medium, for example DMEM or MEM, which also
  • DMSO or glycerol for example 5-20%, preferably about 10% DMSO.
  • the cells suitable for cryopreservation according to the present invention are not especially limited.
  • the cells may be selected from the group
  • prokaryotic cells including bacterial cells and archaebacterial cells
  • eukaryotic cells including animal cells, in particular mammalian cells, plant cells and fungal cells, artificial cells and cell constructs.
  • the cells may be native cells or cells which have been modified, e.g. by means of genetic engineering. Said modification may in particular comprise the introduction of additional cell components (e.g. additional genetic material) , the substitution of native cell components with corresponding components from other native cells or
  • the cells may also be synthetically prepared artificial cells and vesicles, which comprise or consist of components of native cells, in particular membrane components, and are capable to be affected by a signal or effector protein/- peptide as defined above.
  • the term "cells” as used herein refers to complete, vital cells and not cell fragments like blood platelets. Thus, e.g. blood platelets are excluded from this definition of cells.
  • the term "cells” preferably includes nucleus-containing cells as well as erythrocytes.
  • the cells suitable for cryopreservation according to the present invention may be stem cells, differentiated cells, oocytes, or spermatocytes or any other type of cells.
  • the cells may be single cells or part of a cell aggregate, tissue or an organism, including an embryo, preferably a non-human embryo.
  • Fig. 1 shows an Boyle van ⁇ t Hoff plot: passive volume decrease of HepG2 cells as a function of the external osmolarity (cell volume (%) versus osM -1 ) at various temperatures .
  • Fig. 2 shows the transient increase of HICC current
  • Fig. 3 schematically depicts the freezing and thawing process of cells.
  • Fig. 4 shows the relative survival rates of HepG2 and
  • HeLa cells Fig. 4A
  • HDMEC cells Fig. 4B after cryopreservation, wherein the cells have been incubated for 1 h in the presence and absence of vasopressin before starting the cryoprotocol .
  • Fig. 5 shows the proliferation of HepG2, HeLa and HDMEC cells (confluence versus time) cultured without
  • cryopreservation control and after cryopreservation wherein the cells have been incubated for 1 h in the presence and absence of vasopressin before starting the cryoprotocol .
  • HeLa cells and HepG2 cells (a human liver cell line) which both express the a unit of the cation channel ENaC as well as HDMEC cells which do not express aENaC were cultivated under standard conditions (37 °C, 5% C0 2 ) and incubated in a culture medium (e.g. MEM, DMEM or Endothelial Cell Growth Medium MV) for 1 h in the presence and absence of 100 nM vasopressin at 37°C, 5% C0 2 just before cryopreservation. After replacing the vasopressing-containing medium by a fresh culture medium without vasopressin, the cells were cooled to +5°C and 10% DMSO was added. Subsequently the cells were slowly cooled to a target temperature of -50°C or -80°C with a cooling rate of l°C/min.
  • a culture medium e.g. MEM, DMEM or Endothelial Cell Growth Medium MV
  • the cells were stored for a period of time in the range from 2 to 10 days.
  • the survival rates of non-cryopreserved HepG2 and Hela cells were about 95% and 93%, respectively. After cryopreservation, the survival rates dropped to 83% and 81%, respectively. The survival rates considerably increase to about 89% and 88%, respectively, if 100 nM vasopressin is added to the culture medium prior to cryopreservation.
  • Fig. 4B shows that non-cryopreserved HDMEC cells had a survival rate of about 94% which dropped to about 75 % after cryopreservation. Contrary to the above Hela and HepG2 cells, the addition of vasopression had no cryo- protective effect in this system. It is assumed that this critical difference is due to the absence of the
  • Fig. 5 shows the
  • vasopressin further stimulates the proliferation during this entire time period (Fig. 5A) .
  • the stimulating effect of vasopressin is especially pronounced after a cryopreservation .
  • the proliferation of both HepG2 and HeLa cells (cryopreserved for 2 to 10 days at -50°C) is considerable increased during the entire time period.
  • amiloride a drug which is known to block ENaC channels
  • amiloride was also added to HepG2 cells and in the presence of both vasopressin and amiloride the proliferation of the HepG2 cells was drastically decreased after cryopreservation (data not shown) .
  • vasopressin either after a cryopreservation or without (Fig. 5C) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the use of a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of cells for cryoconservation and to a method for cryopreservation of cells using such a signal or effector protein/peptide. The claimed method comprises at least the following steps: a) contacting the cells with a signal or effector protein/peptide having at least one of the following properties : - capable to affect the osmoregulation of cells, - capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells, - capable to affect regulatory processes which involve membrane-bound transporters, for a predetermined time which is sufficient to allow the signal or effector protein/peptide to display a cryoprotective effect on said cells, and b) cooling the cells to a target temperature below 0°C. More specifically, the signal or effector protein/peptide is selected from the group comprising antidiuretic hormones, in particular vasopressin and its derivatives, aldosteron and its derivatives, cytokines, in particular TNF-α, that affect hypertonicity-induced cation channels (HICCs).

Description

Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells
Background of the invention
The present invention relates to the use of a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of cells for cryo- conservation and to a method for cryopreservation of cells using such a signal or effector protein/peptide.
A number of methods for cryopreservation of cells are known in the art and used routinely. Typically, these methods involve a slow cooling process, e.g. with cooling rate of about -l°C/min, to a temperatur well below the freezing point, e.g. around -50°C or even lower, and a relatively fast thawing process (such as 60°C/min). In order to prevent or minimize damage of the cells during the freezing or thawing process, generally the use of cryoyprotectants is considered to be compulsory. Such cryoprotectants may act via different mechanisms. For example, one class of cryoprotectants , such as DMSO or glycerol, reduce the formation of ice crystals in the intracellular and/or extracellular space of the cells. Usually, the freezing or thawing protocol is interrupted at about +5°C in order to add or safely remove the respective cryoprotectant.
Depending on the respective cell type, the survival rates may vary over a wide range. Whereas most cell types have survial rates in the range from about 70-95%, for some cells, e.g. stem cells, the yield may be much lower, such as 1 % or even less.
Other classes of cryoprotectants, such as trehalose and other sugars or various long-chained polymers, are known to "stabilize" the cells and the addition of viscosity- increasing agents, such as gels, has also been reported to slightly improve the survival rates. However, the addition of the latter complicates handling of the samples in the course of temperature changes and returning the cells after thawing to essentially physiological culture conditions.
Considerable efforts have been made in the past to develop further cryoprotectants which are less toxic than the aditives commonly used (in particular DMSO and similar compounds) and which also result in a significant increase of the survival rates and vitality of the cells. However, in the last decades no substances with really improved performance have been added to the list of established cryoprotectants .
Spindler et al. (2012), in Cryobiology 64, 250-260,
describe the use of several compounds, such as DMSO, ethylene glycol, proline and ectoin, as cryoprotectants for cells. No proteins or peptides are disclosed for this purpose.
WO 2005/094806 Al discloses the use of quaternary ammonium compounds which block transport through aquaporines i.a. for use as cryoprotectants. US 5,919,614 Al describes a method for prolonging the preservation of human blod platelets (which are not
completely vital cells and i.a. nucleus-free, thus often denoted as cells fragments) , at reduced temperatures by adding an inhibitor substance which interrupts normal platelet function during storage and enables them to retain their shape. While a great variety of compounds acting via different metabolic pathways are claimed for this purpose, sucessful tests are only presented for a very small number of compounds, such as amiloride, adenosine and sodium nitroprusside .
In view of the drawbacks of the prior art, the main object of the present invention was to provide novel and improved means for the protection of cells during cryopreservation which do not involve the use of toxic compounds, can be readily implemented in established cryopreservation
protocols and which result in a significant increase of the survival rates and vitality (in particular proliferation capability) of the cells.
This objective has been achieved by providing the use of a signal or effector protein/peptide as a cryoprotectant according to claim 1 and the method according to claim 2. Additional aspects and more specific embodiments of the invention are the subject of further claims.
Description of the invention
The present invention provides the use of a signal or effector protein/peptide having at least one of the
following properties:
- capable to affect the osmoregulation of cells, - capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells,
- capable to affect regulatory processes which involve membrane-bound transporters,
as a cryoprotectant for cells.
In a closely related aspect, the present invention provides a method for cryopreservation of cells, which method comprises at least the following steps:
a) contacting the cells with a signal or effector
protein/peptide having at least one of the following properties :
- capable to affect the osmoregulation of cells,
- capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells,
- capable to affect regulatory processes which involve membrane-bound transporters,
for a predetermined time which is sufficient to allow the signal or effector protein/peptide to display a
cryoprotective effect on said cells, and
b) cooling the cells to a target temperature below 0°C.
The term "cryoprotective effect", as used herein, means any effect which, after cryopreservation of target cells, results in an increase of the survival rates and/or
vitality (in particular as measured by the proliferation capability) of said cryopreserved cells. Consequently, a "cryoprotectant" is any agent which causes such an effect. If cells are subjected to a hypertonic stress, e.g. induced by increasing the external osmolarity, at physiological temperatures, i.e. about +35°C, the cells initially react like a osmometer by reducing their volume. This is due to the high water permeability of the plasma membrane caused on the molecular level by the presence of nearly ubiquitary expressed passive water channels, so-called aquaporins .
Subsequently, a "regulatory volume increase" (RVI) of the cells follows which is an active response of the cells wherein an influx of ions according to their respective gradient takes place and concomitantly water is transported by osmosis into the cells. The RVI is mainly realized via "hypertonicity-induced cation channels (HICCs) (Wehner (2006), Contrib. Nephrol. 152, 25-53).
The freezing process during cryopreservation is also known to be accompanied by a dehydration of the cells. For example, at temperatures below -10 °C the formation of extracellular ice crystals results in a thermodynamically driven loss of water through the plasma membrane (Spindler et al. (2012), Cryobiology 64, 250-260).
Further experiments of the present inventors demonstrated that already in the range from +35°C to +10°C a
considerable reduction of the osmotically active portion of a cell, i.e. the aqueous phase, can be observed. Fig. 1 shows that the portion of the aqueous phase decreases from about 69% of the total cell volume at 35°C to about 17% of the total cell volume at 10°C (as indicated by the point of intersection of the regression line with the axis of the cell volume) and which is 25% of the control value at 35°C. The implications associated with the osmoregulation of cells during cryopreservation have been largely disregarded in the past. It is only known to add osmolytes to an external cryomedium in order to assist the dehydration of the cells. A considerable dehydration and concomitant shrinking of the cells is considered to be desirable or even required in order to prevent destruction of the membranes of the cells by the extending ice crystals, to cause the crystallization of less water in the cytoplasm, and to ensure that folded membrane material is available for closing cracks and cryo-defects when the fluidity of the membrane lipids is restored after thawing.
The present inventors postulated that the survival rate and vitality of cryopreserved cells might be improved if the cells are provided with means enabling to revert the
(passive) volume reduction which occurs during the freezing step in the course of the thawing process with increased efficiency. The inventors further postulated that such a means could be the contact with an added signal or effector protein/peptide which affects the osmoregulation and water or ion transporting processes of the target cells to be cryopreserved. In view of published data showing that the peptide hormone vasopressin regulates the activity of aquaporins and of cation channels via specific receptors under physiogical conditions (Stockand (2010), Kidney Int., 78, 849-856; and Boone & Deen (2008), Pflugers Archive - European Journal of Physiology, 456, 1005-1024), this peptide and similar acting compounds appeared to be
promising candidates for a suitable effector.
In the Examples below, it is demonstrated that the addition of vasopressin to target cells to be cryopreserved actually improved the survival rate and viability of such cryo- preserved cells considerably.
Principally, the signal or effector protein/peptide used in the present invention is not especially limited and may be any protein or peptide or compound having at least one of the properties recited in claim 1.
A protein as defined herein comprises a sequence of at least 20 amino acids, such as 20 - 100 amino acids or more, whereas a peptide as defined herein comprises a sequence of about 2 - 19 amino acids, in particular 2 - 10 amino acids. The amino acids may be naturally occurring amino acids or chemically modified derivatives thereof.
More specifically, the signal or effector protein/peptide is selected from the group comprising proteins/peptides which effect the activity of aquaporins, ion, protein or sugar transporting systems. A large number of such ion, protein or sugar transporting systems are well-known in the art and some non-limiting specific examples are NHEl, NKCC1 and SGLT1.
In a preferred embodiment, the signal or effector
protein/peptide affects the activity of aquaporins or ion channels, in particular hypertonicity-induced cation channels (HICCs),for example TRPM2 and aENaC.
Preferably, the signal or effector protein/peptide acts by activating said transporting systems, in particular ion channels as mentioned above, thus, the effector protein/- peptide may be more specifically denoted as an activator protein/peptide . Preferably, the signal or effector protein/peptide is selected from the group comprising antidiuretic hormones, such as the peptide hormone vasopressin and its derivatives, in particular derivatives wherein one or more amino acid substitutions have been effected without essentially diminishing its effector activity (e.g. the amino acid at position 8 may be arginine, lysine or another amino acid) , aldosteron and its derivatives, cytokines, in particular TNF-a, and other proteins/peptides that may affect HICCs.
One example of such a hypertonicity-induced cation channel is the epithelial Na+ channel ENaC and particularly its a subunit ENaC is regulated by vasopressin. aENaC is expressed in a multitude of different cells (including non-epithelial cells as well) . According to the expression atlas EMBL-EB1 (dated 23.4. 2013) 106 cell types and 389 cell lines expressing the same are known so far. Thus, the osmoregulation and other transporting processes mediated by this ion channel of a large number of different cell types can be affected via vasopressin.
For cell types which do not express this specific ion channel, other known signal or effector proteins/peptides which regulate other ion channels can be used in an
analogous manner.
Typically, the signal or effector protein/peptide is present in the medium containing the cells in a
concentration in the range from 1 nM to 1 μΜ, preferably in the range from 10 nM to 500 nM.
The medium may be any suitable medium known in the art, in particular any medium suitable for cultivation and maintainance of the respective cells. The medium may be, e.g. DMEM or MEM.
Preferably, the contacting step is conducted before cooling the cells to a temperature below 0°C.
In a specific embodiment of the method of the invention, the cells are incubated with the signal or effector
protein/peptide for a period in the range from 2 min to 48 hrs, preferably in the range from 1 h to 4 hrs, at a temperature in the range from 40°C to 0°C, preferably from 37°C to 0°C or 37°C to 4°C, more preferred about 37°C to 20°C, before cooling the cells to a temperature below 0°C.
In this embodiment, the cells are preferably essentially separated from the signal or effector protein/peptide, e.g. by means of a medium exchange or dialysis, before cooling the cells to a temperature below 0°C.
Alternatively, the contacting step is conducted after cooling the cells to a temperature below 0°C and thawing the cells to a temperature above 0°C.
In a further alternative embodiment of the method of the invention, a first contacting step is conducted before cooling the cells to a temperature below 0°C and a second contacting step is conducted after cooling the cells to a temperature below 0°C and thawing the cells to a
temperature above 0°C.
Typically, the cells are cooled below 0°C with a cooling rate in the range from -5°C/min to -0.1 °C/min, preferably about -l°C/min, to a temperature in the range from -40°C to -196°C, preferably in the range from -50°C or -80°C to -196°C.
The cryomedium may be any suitable medium known in the art for cryopreservation . More specifically, the cryomedium may be selected from the group comprising a conventional cell culture medium, for example DMEM or MEM, which also
contains DMSO or glycerol, for example 5-20%, preferably about 10% DMSO.
Principally, the cells suitable for cryopreservation according to the present invention are not especially limited. The cells may be selected from the group
comprising prokaryotic cells, including bacterial cells and archaebacterial cells, eukaryotic cells, including animal cells, in particular mammalian cells, plant cells and fungal cells, artificial cells and cell constructs.
The cells may be native cells or cells which have been modified, e.g. by means of genetic engineering. Said modification may in particular comprise the introduction of additional cell components (e.g. additional genetic material) , the substitution of native cell components with corresponding components from other native cells or
artificial constructs, and the deletion of specific cell components as well as combinations thereof.
The cells may also be synthetically prepared artificial cells and vesicles, which comprise or consist of components of native cells, in particular membrane components, and are capable to be affected by a signal or effector protein/- peptide as defined above. Preferably, the term "cells" as used herein refers to complete, vital cells and not cell fragments like blood platelets. Thus, e.g. blood platelets are excluded from this definition of cells. In the case of animal cells, in particular mammalian cells, the term "cells" preferably includes nucleus-containing cells as well as erythrocytes.
The cells suitable for cryopreservation according to the present invention may be stem cells, differentiated cells, oocytes, or spermatocytes or any other type of cells.
The cells may be single cells or part of a cell aggregate, tissue or an organism, including an embryo, preferably a non-human embryo.
Brief Description of the Figures
Fig. 1 shows an Boyle van~t Hoff plot: passive volume decrease of HepG2 cells as a function of the external osmolarity (cell volume (%) versus osM-1) at various temperatures .
Fig. 2 shows the transient increase of HICC current
densities (pA/pF) of cryopreserved HeLa cells after
thawing .
Fig. 3 schematically depicts the freezing and thawing process of cells.
Fig. 4 shows the relative survival rates of HepG2 and
HeLa cells (Fig. 4A) and HDMEC cells (Fig. 4B) after cryopreservation, wherein the cells have been incubated for 1 h in the presence and absence of vasopressin before starting the cryoprotocol .
Fig. 5 shows the proliferation of HepG2, HeLa and HDMEC cells (confluence versus time) cultured without
cryopreservation (control) and after cryopreservation wherein the cells have been incubated for 1 h in the presence and absence of vasopressin before starting the cryoprotocol .
The following non-limiting examples are provided to illustrate the present invention in more detail, however, without limiting the same to the specific features and parameters thereof.
EXAMPLE 1
Cryopreservation of cells in the absence and presence of vasopressin
HeLa cells and HepG2 cells (a human liver cell line) which both express the a unit of the cation channel ENaC as well as HDMEC cells which do not express aENaC were cultivated under standard conditions (37 °C, 5% C02) and incubated in a culture medium (e.g. MEM, DMEM or Endothelial Cell Growth Medium MV) for 1 h in the presence and absence of 100 nM vasopressin at 37°C, 5% C02 just before cryopreservation. After replacing the vasopressing-containing medium by a fresh culture medium without vasopressin, the cells were cooled to +5°C and 10% DMSO was added. Subsequently the cells were slowly cooled to a target temperature of -50°C or -80°C with a cooling rate of l°C/min.
The cells were stored for a period of time in the range from 2 to 10 days.
EXAMPLE 2
Characterization of cryopreserved cells
The survival rates of Hela, HepG2 and HDMEC cells which had been cryopreserved according to the protocol of Example 1 and of corresponding non-cryopreserved control cells were quantitatively determined with a coulter counter.
As shown in Fig. 4A, the survival rates of non-cryopreserved HepG2 and Hela cells were about 95% and 93%, respectively. After cryopreservation, the survival rates dropped to 83% and 81%, respectively. The survival rates considerably increase to about 89% and 88%, respectively, if 100 nM vasopressin is added to the culture medium prior to cryopreservation.
Fig. 4B shows that non-cryopreserved HDMEC cells had a survival rate of about 94% which dropped to about 75 % after cryopreservation. Contrary to the above Hela and HepG2 cells, the addition of vasopression had no cryo- protective effect in this system. It is assumed that this critical difference is due to the absence of the
vasopressin-regulated cation channel aENaC in HDMEC cells. In a further experiment, the proliferation of Hela, HepG2 and HDMEC cells has been studied. Fig. 5 shows the
proliferation of these cell types in a range of 0 to 72 hours after commencement of a cultivation. Here, the electric impedance was used to indicate the degree of confluence of a monolayer ("xCELLigence"-system, Roche) . In the control, non-cryopreserved HepG2 cells reach their maximal value after about 30 h and the presence of
vasopressin further stimulates the proliferation during this entire time period (Fig. 5A) . The same applies to the proliferation of HeLa cells in the presence of vasopressin (Fig. 5B) . However, the stimulating effect of vasopressin is especially pronounced after a cryopreservation . The proliferation of both HepG2 and HeLa cells (cryopreserved for 2 to 10 days at -50°C) is considerable increased during the entire time period.
In a supplemental experiment, amiloride, a drug which is known to block ENaC channels, was also added to HepG2 cells and in the presence of both vasopressin and amiloride the proliferation of the HepG2 cells was drastically decreased after cryopreservation (data not shown) .
In contrast to this findings for HepG2 and HeLa cells, the proliferation of HDMEC cells was not significantly
increased by vasopressin either after a cryopreservation or without (Fig. 5C) .
In patch clamp experiments with HepG2 and HeLa cells which were reverted to physiological temperatures after a
cryopreservation, a considerable transient increase of the HICC activity (as indicated by increased current densities) was observed (Fig. 2) . This finding supports the hypothesis that HICC channels are strongly involved in the rehydration of cells after a cryopreservation treatment and that the beneficial effect of vasopressin is mainly due to a
stimulation of this necessary rehydration.

Claims

Use of a signal or effector protein/peptide having at least one of the following properties:
- capable to affect the osmoregulation of cells,
- capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells,
- capable to affect regulatory processes which involve membrane-bound transporters, as a cryoprotectant for cells.
A method for cryopreservation of cells, comprising at least the following steps:
a) contacting the cells with a signal or effector protein/peptide having at least one of the following properties :
- capable to affect the osmoregulation of cells,
- capable to affect general transporting processes in cells which result in notable differences of the physiological parameters of cooled cells before and after freezing and/or of the distribution of osmolytes and water in said cells,
- capable to affect regulatory processes which involve membrane-bound transporters, for a predetermined time which is sufficient to allow the signal or effector protein/peptide to display a cryoprotective effect on said cells, and
b) cooling the cells to a target temperature below
0°C.
3. The method according to claim 2, wherein the cells
are provided in a medium and the signal or effector protein/peptide is present in the medium in an
effective concentration to act as a cryoprotectant for the cells.
4. The method according to claim 3, wherein the signal or effector protein/peptide is present in the medium in a concentration in the range from 1 nM to 1 μΜ, preferably 10 nM to 500 nM.
5. The method according to any one of claims 2 to 4,
wherein the contacting step is conducted before cooling the cells to a temperature below 0°C.
6. The method according to claim 5, wherein the cells are incubated with the signal or effector protein/peptide for a period in the range from 2 min to 48 hrs, preferably in the range from 1 h to 4 hrs, before cooling the cells to a temperature below 0°C.
7. The method according to claim 5 or 6, wherein the
cells are separated from the signal or effector protein/peptide, e.g. by means of a medium exchange or dialysis, before cooling the cells to a temperature below 0°C.
8. The method according to any one of claims 2 to 4, wherein the contacting step is conducted after
cooling the cells to a temperature below 0°C and thawing the cells to a temperature above 0°C or wherein a first contacting step is conducted before cooling the cells to a temperature below 0°C and a second contacting step is conducted after cooling the cells to a temperature below 0°C and thawing the cells to a temperature above 0°C.
9. The method according to any one of claims 2-8, wherein the cells are cooled below 0°C with a cooling rate in the range from -5°C/min to -0.1°C/min, preferably about -l°C/min, to a temperature in the range from -40°C to -196°C.
10. The use according to claim 1 or the method according to claims 2-9, with the proviso that the cells are not blood platelets or other cell fragments.
11. The use or method according to any one of claims 1-10, wherein the signal or effector protein/peptide is selected from the group comprising antidiuretic hormones, in particular vasopressin and its
derivatives, aldosteron and its derivatives, and cytokines, in particular TNF-oc, that affect
hypertonicity-induced cation channels (HICCs) .
12. The use or method according to any one of claims 1-11, wherein the signal or effector protein/peptide
affects, in particular induces or stimulates, the activity of aquaporins, ion, protein or sugar
transporting systems. The use or method according to claim 12, wherein the signal or effector protein/peptide affects the
activity of aquaporins or ion channels, in particular HICCs.
The use or method according to any one of the
preceding claims, wherein the cells are selected from the group comprising prokaryotic cells and eukaryotic cells, including animal cells, in particular mammalian cells, plant cells and fungal cells, artificial cells and cell constructs.
The use or method according to claim 14, wherein the cells are stem cells, differentiated cells, oocytes, or spermatocytes.
The use or method according to claim 14 or 15, wherein the cells are part of a cell aggregate, tissue or an organism, including an embryo.
EP14718919.5A 2013-04-30 2014-04-16 Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells Withdrawn EP2991480A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14718919.5A EP2991480A1 (en) 2013-04-30 2014-04-16 Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002322.9A EP2798953A1 (en) 2013-04-30 2013-04-30 Method for cyropreservation of cells using a signal or effector protein/ peptide/compound which affects the osmoregulation or general transporting prcoesses of the cells
PCT/EP2014/001028 WO2014177252A1 (en) 2013-04-30 2014-04-16 Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells
EP14718919.5A EP2991480A1 (en) 2013-04-30 2014-04-16 Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells

Publications (1)

Publication Number Publication Date
EP2991480A1 true EP2991480A1 (en) 2016-03-09

Family

ID=48226933

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13002322.9A Withdrawn EP2798953A1 (en) 2013-04-30 2013-04-30 Method for cyropreservation of cells using a signal or effector protein/ peptide/compound which affects the osmoregulation or general transporting prcoesses of the cells
EP14718919.5A Withdrawn EP2991480A1 (en) 2013-04-30 2014-04-16 Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13002322.9A Withdrawn EP2798953A1 (en) 2013-04-30 2013-04-30 Method for cyropreservation of cells using a signal or effector protein/ peptide/compound which affects the osmoregulation or general transporting prcoesses of the cells

Country Status (2)

Country Link
EP (2) EP2798953A1 (en)
WO (1) WO2014177252A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7323290B2 (en) * 2015-11-16 2023-08-08 アクロン・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー Cryopreserved compositions and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919614A (en) * 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
WO2005094806A1 (en) * 2004-03-31 2005-10-13 Stichting Katholieke Universiteit Use of quaternary ammonium compounds as specific blockers of transport through aquaporin, compositions comprising the compounds and method of selecting the compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAFEDIN BEQAJ ET AL: "IDENTIFICATION OF CELLS RESPONSIBLE FOR UROKINASE-TYPE PLASMINOGEN ACTIVATOR SYNTHESIS AND SECRETION IN HUMAN DIPLOID KIDNEY CELL CULTURES", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY - ANIMAL, vol. 40, no. 3, 1 March 2004 (2004-03-01), NEW YORK, pages 102, XP055314120, ISSN: 1543-706X, DOI: 10.1290/1543-706X(2004)040<0102:IOCRFU>2.0.CO;2 *

Also Published As

Publication number Publication date
EP2798953A1 (en) 2014-11-05
WO2014177252A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
Jang et al. Cryopreservation and its clinical applications
Chaytor et al. Inhibiting ice recrystallization and optimization of cell viability after cryopreservation
Jahan et al. Current and future perspectives for the cryopreservation of cord blood stem cells
US8017311B2 (en) Method for treatment of cellular materials with sugars prior to preservation
Milford et al. Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage
Liang et al. Effect of antifreeze glycoprotein 8 supplementation during vitrification on the developmental competence of bovine oocytes
CA2522941A1 (en) Improved methods and solutions for storing donor organs
WO2013117925A1 (en) Cryopreservation of cells in absence of vitrification inducing agents
EP2934110A1 (en) Use of connexin channel inhibitors to protect grafts
Jerez-Ebensperger et al. Effect of pasteurized egg yolk and rosemary honey supplementation on quality of cryopreserved ram semen
Kanias et al. Mammalian cell desiccation: facing the challenges
Stoll et al. Membrane stability during biopreservation of blood cells
Waters et al. Strategies to improve platelet cryopreservation: A narrative review
CA2683858A1 (en) Ergothioneine and/or its derivatives as a cell preservative
Johnson et al. A deep eutectic solvent is an effective cryoprotective agent for platelets
CN113490414B (en) Preservation of Stem cells
EP2991480A1 (en) Method for cryopreservation of cells using a signal or effector protein/peptide which affects the osmoregulation or general transporting processes of the cells
US20080286863A1 (en) Method and solutions for cryopreserving oocytes, especially fresh human oocytes
Monteiro et al. Effect of antifreeze protein type III on frozen/thawed of spermatozoa recover from goat epididymis
Balint et al. Cellular cryobiology: A review of basic concepts and" operating design" of cryopreserved cells
Bohoněk Cryopreservation of blood
JP2014198673A (en) Preservative for low temperature storage of animal embryo and method of storing animal embryo at low temperature
WO2019175596A1 (en) Cryopreserving processes
KR100476790B1 (en) A cell preservation solution and the freezing and preservation procedures of animal cells using the said solution
Tomalty et al. Chilling injury in human kidney tubule cells after subzero storage is not mitigated by antifreeze protein addition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170314